Skip to main content

Table 1 Baseline characteristics according to sex-stratified tertiles of RLP cholesterol

From: Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies

Variable (n = 480)

T1 (low tertile), n = 151

T2 (middle tertile), n = 180

T3 (high tertile), n = 149

P value for trend

RLP cholesterol (mmol/L)

0.3 [0.2–0.4]

0.6 [0.5–0.7]

1.1 [0.9–1.4]

 < 0.001

General characteristics

 Age (years)

53.6 [40.7–62.3]

53.8 [41.3–62.7]

53.1 [44.7–61.3]

0.902

 Male sex (%)

49.0

63.3

59.1

0.029

Smoking status

 Never smoker (%)

47.9

40.8

37.0

0.159

 Former smoker (%)

41.7

49.4

41.8

0.271

 Current smoker (%)

10.4

9.8

21.2

0.005

Alcohol consumption

 None (%)

12.7

8.4

9.5

0.430

 0–10 g/day (%)

63.3

59.6

59.9

0.750

 10–30 g/day (%)

18.0

26.4

25.2

0.166

 > 30 g/day (%)

6.0

5.6

5.4

0.978

Body composition

 BMI (kg/m2)

24.8 [22.1–28.1]

25.6 [23.2–27.7]

26.4 [23.3–29.9]

0.017

 Waist circumference (cm)

95.0 ± 15.7

96.3 ± 13.5

98.6 ± 13.1

0.096

Transplant history

 Time since renal transplantation (years)

7.0 [4.0–12.0]

6.0 [2.3–12.0]

4.0 [1.0–12.0]

0.019

 Deceased donor (%)

65.5

64.4

63.1

0.904

 Donor age (years)

44.0 [29.0–53.0]

46.0 [31.0–55.8]

48.0 [34.0–56.0]

0.263

 Dialysis duration (months)

42.5 [13.0–62.8]

48.0 [23.0–64.5]

32.0 [16.0–54.0]

0.234

 Acute rejection (%)

19.2

25.0

27.5

0.221

 HLA class I positive (%)

10.6

11.1

10.1

0.700

 HLA class II positive (%)

14.6

11.7

10.7

0.819

Renal allograft function

 Serum creatinine (µmol/L)

112.0 [92.0–140.3]

122.0 [101.0–152.0]

139.0 [109.0–178.5]

 < 0.001

 eGFR (mL/min/1.73 m2)

55.9 [42.4–70.2]

52.9 [42.3–64.1]

43.9 [30.3–61.0]

 < 0.001

 Urinary albumin-to-creatinine ratio (UACR)

28.4 [6.6–100.5]

25.3 [7.8–115.2]

32.3 [7.8–158.6]

0.683

 Proteinuria (≥ 0.5 g/24 h) (%)

17.2

22.2

21.5

0.493

Inflammation markers

 hsC-reactive protein (mg/L)

1.2 [0.5–3.3]

1.4 [0.6–4.5]

1.6 [0.8–4.0]

0.254

Blood pressure

 Diastolic blood pressure (mmHg)

82.9 ± 11.3

82.3 ± 10.9

83.9 ± 10.5

0.447

 Systolic blood pressure (mmHg)

133.0 [122.0–142.0]

135.0 [125.0–146.0]

135.0 [125.0–145.5]

0.297

Glucose homeostasis

 Plasma glucose (mmol/L)

5.1 [4.7–5.4]

5.0 [4.7–5.5]

5.2 [4.7–5.6]

0.605

 HbA1c (mmol/mol)

38.0 [36.0–41.0]

39.0 [36.0–41.0]

39 [36.0–42.0]

0.479

 HbA1c (%)

5.6 [5.4–5.9]

5.7 [5.4–5.9]

5.7 [5.4–6.0]

0.479

Lipids and lipoproteins

 Total cholesterol (mmol/L)

4.7 [4.1–5.5]

4.8 [4.3–5.5]

5.6 [5.0–6.3]

 < 0.001

 LDL cholesterol (mmol/L)

2.8 [2.2–3.4]

2.8 [2.3–3.3]

3.0 [2.6–3.6]

0.004

 HDL cholesterol (mmol/L)

1.5 [1.2–1.9]

1.3 [1.1–1.6]

1.2 [1.0–1.4]

 < 0.001

 Triglycerides (mmol/L)

1.2 [1.0–1.4]

1.6 [1.3–1.9]

2.4 [1.9–3.0]

 < 0.001

Medication use

 Antihypertensives (%)

85.4

87.2

87.2

0.864

 Statins (%)

43.7

51.1

54.4

0.165

 Proliferation inhibitor (%)

84.1

86.7

83.9

0.730

 Calcineurin inhibitor (%)

46.4

59.4

59.1

0.030

 Tacrolimus (%)

13.2

15.6

16.8

0.686

 Cyclosporine (%)

33.1

39.4

36.2

0.490

 Prednisolone (mg/24 h)

10.0 [7.5–10.0]

10.0 [7.5–10.0]

10.0 [7.5–10.0]

0.183

  1. Continuous data with normal distribution are shown as mean ± standard deviation, differences were tested using one-way ANOVA. Continuous data with skewed distribution are shown as median [IQR] and the differences were tested using Kruskal–Wallis test. Categorical data are shown as n (%) and differences were analyzed using the chi-square test